Last updated: June 6, 2026
Brevidol (BreviBloc) Double Strength in Plastic Container: Who Supplies It, Manufacturing Sources, and Contract Landscape
BreviBloc Double Strength in a plastic container is a branded supply product of Eli Lilly. In the US distribution chain, the product is typically supplied through Lilly’s commercial supply network (primary manufacturer and labeler), with distribution handled by Lilly and its logistics partners rather than by a visible set of independent “drug substance” or “finished dose” suppliers in public drug master files.
What suppliers make Brevibloc double strength in plastic container?
Answer: The primary finished-dose supply is by the product’s labeler/manufacturer (Eli Lilly), with distribution through Lilly’s channels.
Because “suppliers” in pharmaceutical search usually means one of three things, the key distinction matters:
- Labeler/manufacturer of record (finished dosage, US-registered firm)
- API (active ingredient) suppliers
- Contract manufacturing/packaging suppliers (CMO/CDMO for fill-finish, plastic container assembly, and labeling)
For BreviBloc (metoprolol hydrochloride) “Double Strength” in plastic container, the publicly visible supplier answer is dominated by the labeler/manufacturer of record rather than named API or packaging suppliers. In practice, the supplier landscape tends to look like:
- Primary manufacturer of record: the brand owner’s registered manufacturing site(s)
- Fill-finish and packaging: controlled by Lilly or by Lilly’s contract partners, but those partners are not consistently indexed under a simple “supplier list” in public sources
Commercial implication: third-party supplier identification for sourcing bids, qualification, or switching tends to require Orange Book/labeler cross-checks, FDA facility/DMF mapping, and inspection history review rather than a straightforward “vendor roster.”
Which companies are the labeler and finished-dose manufacturer for Brevibloc double strength?
Answer: The labeler/manufacturer of record is Eli Lilly.
For BreviBloc products, the “supplier” most relevant for procurement, tendering, and substitution is the US labeler listed on FDA labeling. The labeler ties to:
- FDA registration for manufacturing/processing
- lot release chain
- product-specific packaging configuration (double strength, container type)
- labeling responsibility
Procurement note: when a buyer requests “suppliers,” the correct compliance response is to anchor to:
- Labeler/Holder on the prescribing information
- NDC-specific listing and manufacturing site (where available)
- GMP inspection footprint for that firm and dosage form
What role do CDMOs and packaging vendors play for Brevibloc plastic containers?
Answer: Fill-finish and packaging are usually handled under Lilly-controlled quality agreements; publicly enumerated CDMO names are inconsistent.
BreviBloc “double strength” in a plastic container implies:
- solution formulation and final fill
- primary packaging into the plastic container configuration
- secondary packaging and labeling
- sterility assurance (if applicable to that dosage form) or other process controls depending on product design
In many injectable and parenteral solution products, companies split work across:
- bulk manufacturing (API and/or drug product intermediate)
- sterile fill-finish
- container/closure and assembly lines
- label and kitting
For branded supply products like BreviBloc, contract packaging and fill-finish suppliers tend to be:
- named at the manufacturing site level in some FDA registrant disclosures
- embedded contractually rather than marketed as standalone “suppliers”
Procurement risk: swapping packaging vendors or changing container supplier typically requires regulatory comparability work, stability bridging, and chemistry manufacturing controls updates.
Do Brevibloc double strength suppliers include multiple manufacturing sites?
Answer: Brand supply often supports redundancy via alternate manufacturing sites, but the public “supplier list” is not consistently exposed by container strength and packaging form.
In practice, the supplier landscape for supply continuity can include:
- alternative fill-finish sites under the same labeler
- container and closure supplier alternates
- label and distributor logistics alternates
For “double strength in plastic container,” buyers often see different NDCs tied to specific packaging configurations, and those NDCs may map to different manufacturing site codes.
Commercial implication: allocation changes and shortages often happen at the fill-finish and packaging step, not only at API synthesis.
How can procurement teams identify the real supplier of Brevibloc double strength plastic container?
Answer: Use NDC mapping to the labeler/manufacturer of record and then trace registered manufacturing sites.
A defensible procurement method is:
- confirm the exact NDC for “double strength” and “plastic container”
- match the NDC to FDA labeling/holder information (labeler)
- pull the FDA facility registration mapping for the manufacturing step associated with that NDC, when indexed
- check recent GMP inspection outcomes for that site(s)
- require a COA and lot-level traceability that includes manufacturing site and packaging line where permitted
This is the approach procurement uses for:
- vendor qualification
- substitution testing
- supply risk scoring
- regulatory audit readiness
Which API suppliers are involved for metoprolol hydrochloride (BreviBloc)?
Answer: API suppliers are not reliably identified as a public “supplier list” for BreviBloc finished-dose products.
Metoprolol hydrochloride is a well-established small-molecule API with a global supplier base. However:
- the API supplier for a specific branded finished-dose NDC is not consistently disclosed
- Lilly’s quality system can source from multiple DMF or supplier qualification routes
- DMF or alternative sourcing is often controlled by regulatory and quality agreements
Operational implication: if your use case is API supply continuity, you generally have to determine:
- whether the finished-dose product uses DMF-referenced API grades
- whether the labeler uses more than one API source
- whether the API supplier change triggers a regulatory comparability package for that NDC
What manufacturing/IP barriers exist for Brevibloc double strength plastic container?
Answer: Barriers are mainly regulatory and quality-driven, not a simplistic “supplier exclusivity.”
Key constraints for alternative supply:
- container/closure system qualification for that product configuration
- process validation for solution fill-finish
- sterility assurance and aseptic control where applicable
- stability and shelf-life justification for packaging changes
- labeling comparability for strength and container type
On the IP side, the supplier landscape is shaped by:
- whether the product has active Orange Book patents tied to the finished dosage form
- whether method-of-use claims cover clinical use of metoprolol for specific settings
But for procurement decisions focused on “supplier,” the binding constraints tend to be regulatory and CMC.
How does the supplier landscape change if a buyer considers generic or biosimilar alternatives?
Answer: Generics are chemically identical for metoprolol products; supplier switching risk shifts to CMO fill-finish and regulatory ANDA approval status.
BreviBloc is not a biologic, so “biosimilar” is not applicable. For generic alternatives:
- supplier decisions depend on which ANDA or 505(j) listing maps to the same strength and container type
- product substitution requires matching dosage form, concentration, and container configuration, plus pharmacy substitution policies
If multiple generic SKUs exist for similar presentations, buyers often have more supplier leverage via:
- multiple ANDA holders
- multiple fill-finish sites
- independent lot release schedules
Key Takeaways
- The practical “supplier” for BreviBloc Double Strength in plastic containers is Eli Lilly as the labeler/manufacturer of record for US distribution.
- Publicly indexed “API supplier rosters” and “packaging vendor names” are usually not exposed in a simple supplier list for this specific branded NDC presentation.
- Procurement identification should be NDC-driven: confirm NDC, map to labeler/holder, then trace registered manufacturing sites and lot-level traceability requirements.
- Any alternative supply path for similar presentations is typically limited by fill-finish, container/closure qualification, sterility/aseptic controls where relevant, and CMC comparability rather than by a single named vendor exclusivity.
FAQs
1) Who is the labeler for BreviBloc Double Strength in plastic container?
Eli Lilly (as product holder/labeler of record for the US presentation).
2) Is BreviBloc a biologic with biosimilar suppliers?
No. It is a small-molecule metoprolol product, so the relevant alternatives are generics/ANDA holders, not biosimilars.
3) Are API suppliers for metoprolol disclosed for BreviBloc?
They are typically not disclosed as a public “supplier list” tied to the finished-dose NDC.
4) Can different container suppliers be used for the same BreviBloc presentation?
Changes can occur under controlled quality systems, but they require comparability and CMC validation for the specific packaging configuration.
5) What is the fastest way to verify the manufacturing firm for a specific BreviBloc SKU?
Map the exact NDC to FDA labeling/holder information and verify lot-level manufacturing site details via COA/traceability documentation.
References
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. Drug Registration and Listing System (DRLS).
- FDA. Labeling and NDC information via SPL (Structured Product Labeling) for BreviBloc products.
